Aadi Bioscience Enters Material Definitive Agreement
Ticker: WHWK · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1422142
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
TL;DR
AADI signed a big deal on April 1st, 2024.
AI Summary
On April 1, 2024, Aadi Bioscience, Inc. entered into a Material Definitive Agreement. The company, formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates a significant contractual development for Aadi Bioscience, which could impact its business operations and future strategic direction.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities that may significantly affect a company's financial performance and stock price.
Key Players & Entities
- Aadi Bioscience, Inc. (company) — Registrant
- April 1, 2024 (date) — Date of earliest event reported
- Aerpio Pharmaceuticals, Inc. (company) — Former company name
- Zeta Acquisition Corp II (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the nature of the Material Definitive Agreement entered into by Aadi Bioscience, Inc. on April 1, 2024?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on April 1, 2024.
What was Aadi Bioscience, Inc. previously known as?
Aadi Bioscience, Inc. was formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acquisition Corp II.
In which state is Aadi Bioscience, Inc. incorporated?
Aadi Bioscience, Inc. is incorporated in Delaware.
What is the SIC code for Aadi Bioscience, Inc.?
The Standard Industrial Classification (SIC) code for Aadi Bioscience, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for Aadi Bioscience, Inc.?
The principal executive offices of Aadi Bioscience, Inc. are located at 17383 Sunset Boulevard, Suite A250, Pacific Palisades, California 90272.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-04-04 16:08:39
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share AADI The Nasdaq Stock Marke
Filing Documents
- aadi-20240401.htm (8-K) — 23KB
- 0001628280-24-014876.txt ( ) — 147KB
- aadi-20240401.xsd (EX-101.SCH) — 2KB
- aadi-20240401_lab.xml (EX-101.LAB) — 22KB
- aadi-20240401_pre.xml (EX-101.PRE) — 13KB
- aadi-20240401_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On April 1, 2024, Aadi Bioscience, Inc. (the "Company") entered into Amendment No.2 (the "Amendment") to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius Kabi, LLC ("Fresenius Kabi"). The Amendment is effective as of March 31, 2024. Pursuant to the Amendment, among other things, the term of the Agreement is extended until July 31, 2024 (or such later date as may be agreed upon between the parties), and certain terms related to pricing, forecasting, compliance and the Company's obligation to purchase certain minimum quantities of FYARRO from Fresenius Kabi have been updated and revised. The Amendment contains other customary terms applicable to the manufacture of therapeutics in the biotechnology industry. The foregoing summary is not complete and is qualified in its entirety by reference to the Amendment, which will be filed as an exhibit in a subsequent periodic report of the Company to be filed under the Securities Exchange Act of 1934, as amended.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. April 4, 2024 /s/ Scott Giacobello Scott Giacobello Chief Financial Officer